Business
Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association’s 85th Scientific Sessions with Simultaneous Publication in Diabetes Care
Treatment with a cortisol modulator significantly improves glucose control in patients with hypercortisolism and difficult-to-control diabetes, accompanied
About this update from Corcept Therapeutics Incorporated
[{"type":"text","content":"\n\nTreatment with a cortisol modulator significantly improves glucose control in patients with hypercortisolism and difficult-to-control diabetes, accompanied by reductions in body weight, waist circumference and glucose-lowering medications\n\n\n\nCATALYST’s prevalence phase identified hypercortisolism in 24 percent of patients with difficult-to-control type 2 diabetes\n\n\n\n REDWOOD CITY, Calif.--(BUSINESS WIRE)--\nCorcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today presented data from the randomized, double-blind, placebo-controlled treatment phase of its CATALYST trial of Korlym® in patients with hypercortisolism (Cushing’s syndrome) and difficult-to-control type 2 diabetes at the American Diabetes Association’s 85th Scientific Sessions.\n\n\nCATALYST met its primary endpoint. Patients who received Korlym exhibited a clinically meaningful and statistically significant improvement in hemoglobin A1c (HbA1c), which decreased 1.47 percent from baseline, compared to a 0.15 percent decrease in patients who received placebo (p-value: 20% of participants receiving Korlym) were hypokalemia, fatigue and nausea.\n\n\nThe conference presentations can be found here. Results were published simultaneously in Diabetes Care, in an article titled “Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment.”\n\n\nCATALYST is the largest and most rigorous trial ever conducted to determine the prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes and assess the effect of treating patients found to have hypercortisolism with a cortisol modulator. The initial prevalence phase of the trial screened 1,057 patients with difficult-to-control type 2 diabetes (i.e., patients with HbA1c greater than 7.5 percent despite receiving multiple glucose-lowering medications, including best-in-class therapies such as GLP-1 agonists) at 36 sites in the United States. Based on results from a standard 1-mg dexamethasone suppression test, 24 percent of the patients screened were found to have hypercortisolism and were eligible to enter the trial’s treatment phase, where they...